Form 4: Axsome CEO Herriot Tabuteau Granted 54,623 RSUs

Axsome Therapeutics CEO Herriot Tabuteau received a grant of 54,623 Restricted Stock Units, vesting over four years.

Summary

• Herriot Tabuteau, Chief Executive Officer, Director, and 10% Owner of Axsome Therapeutics, Inc. (AXSM), was granted 54,623 Restricted Stock Units (RSUs).
• The transaction date for this grant was February 26, 2026.
• Each RSU represents a contingent right to receive one share of Axsome Therapeutics' common stock.
• The RSUs will vest over a four-year period: 25% on the one-year anniversary of the grant date (February 26, 2027), with the remaining RSUs vesting in three substantially equal annual installments, leading to full vesting by February 26, 2030.
• Vested shares will be delivered to Dr. Tabuteau upon the earliest of a Change in Control, his separation of service from the Issuer, or seven years from the date of grant (February 26, 2033).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management's interests with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The RSU grant aligns the Chief Executive Officer's long-term interests with those of shareholders, incentivizing sustained company performance.
• The vesting schedule encourages long-term commitment and retention of key management.

Future Outlook

The RSU grant and its vesting schedule indicate a long-term commitment from the Chief Executive Officer to Axsome Therapeutics, with incentives tied to future performance and share value appreciation over the next several years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value creation. This practice is standard for retaining key leadership and motivating performance in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are a standard component of executive compensation packages across the pharmaceutical and biotech sectors, comparable to practices at companies like Biogen, Gilead Sciences, and Amgen.
• The structure, including a one-year cliff followed by annual installments, is a widely adopted model to ensure executive retention and incentivize sustained performance over several years.

Corporate Governance

Related Party Transactions

• The grant of 54,623 Restricted Stock Units to Herriot Tabuteau, the Chief Executive Officer, Director, and 10% Owner, constitutes a related party transaction as it involves compensation to a key executive and significant shareholder.

Stakeholder Impact

• Shareholders: The RSU grant aims to align the CEO's financial interests with long-term shareholder value creation, potentially leading to improved company performance. However, it also represents potential future dilution upon vesting and delivery of shares.
• Employees: The grant to the CEO may serve as a benchmark or signal for the company's overall compensation philosophy, potentially impacting morale and retention strategies for other key personnel.

Next Steps

• The RSUs will begin vesting on February 26, 2027, with subsequent vesting installments annually until February 26, 2030.
• Vested shares will be delivered to the reporting person upon the earliest of a Change in Control, separation of service, or February 26, 2033.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Herriot Tabuteau, Restricted Stock Units, RSU grant, executive compensation, insider transaction, Form 4, corporate governance